|
1
|
Wang N, Zhu WX, Xing XM, et al: Time
trends of cancer incidence in urban Beijing, 1998–2007. Chin J
Cancer Res. 23:15–20. 2011.
|
|
2
|
Goodwin RA and Asmis TR: Overview of
systemic therapy for colorectal cancer. Clin Colon Rectal Surg.
22:251–256. 2009.
|
|
3
|
Quasar Collaborative Group. Gray R,
Barnwell J, et al: Adjuvant chemotherapy versus observation in
patients with colorectal cancer: a randomised study. Lancet.
370:2020–2029. 2007.
|
|
4
|
André T, Boni C, Navarro M, et al:
Improved overall survival with oxaliplatin, fluorouracil, and
leucovorin as adjuvant treatment in stage II or III colon cancer in
the MOSAIC trial. J Clin Oncol. 27:3109–3116. 2009.
|
|
5
|
Voorneveld PW, Jacobs RJ, De Miranda NF,
et al: Evaluation of the prognostic value of pSMAD
immunohistochemistry in colorectal cancer. Eur J Cancer Prev.
22:420–424. 2013.
|
|
6
|
Saito S, Okabe H, Watanabe M, et al:
CD44v6 expression is related to mesenchymal phenotype and poor
prognosis in patients with colorectal cancer. Oncol Rep.
29:1570–1578. 2013.
|
|
7
|
Bahnassy AA, Zekri AR, Alam El-Din HM, et
al: The role of cyclins and cyclins inhibitors in the multistep
process of HPV-associated cervical carcinoma. J Egypt Natl Canc
Inst. 18:292–302. 2006.
|
|
8
|
Taghavi N, Biramijamal F, Sotoudeh M, et
al: p16INK4a hypermethylation and p53, p16 and MDM2 protein
expression in esophageal squamous cell carcinoma. BMC Cancer.
10:1382010.
|
|
9
|
Bartkova J, Rajpert-De Meyts E, Skakkebaek
NE, et al: Deregulation of the G1/S-phase control in human
testicular germ cell tumours. APMIS. 111:252–266. 2003.
|
|
10
|
Macaluso M, Montanari M, Cinti C and
Giordano A: Modulation of cell cycle components by epigenetic and
genetic events. Semin Oncol. 32:452–457. 2005.
|
|
11
|
Gordon GM, Zhang T, Zhao J and Du W:
Deregulated G1-S control and energy stress contribute to the
synthetic-lethal interactions between inactivation of RB and
TSC1/TSC2. J Cell Sci. 126:2004–2013. 2013.
|
|
12
|
Sun CH, Chang YH and Pan CC: Activation of
the PI3K/Akt/mTOR pathway correlates with tumour progression and
reduced survival in patients with urothelial carcinoma of the
urinary bladder. Histopathology. 58:1054–1063. 2011.
|
|
13
|
Perisanidis C, Perisanidis B, Wrba F, et
al: Evaluation of immunohistochemical expression of p53, p21, p27,
cyclin D1, and Ki67 in oral and oropharyngeal squamous cell
carcinoma. J Oral Pathol Med. 41:40–46. 2012.
|
|
14
|
Strimpakos AS, Karapanagiotou EM, Saif MW
and Syrigos KN: The role of mTOR in the management of solid tumors:
an overview. Cancer Treat Rev. 35:148–159. 2009.
|
|
15
|
Asano T, Yao Y, Zhu J, et al: The PI
3-kinase/Akt signaling pathway is activated due to aberrant Pten
expression and targets transcription factors NF-kappaB and c-Myc in
pancreatic cancer cells. Oncogene. 23:8571–8580. 2004.
|
|
16
|
Jin C, Wang A, Chen J, et al: Relationship
between expression and prognostic ability of PTEN, STAT3 and VEGF-C
in colorectal cancer. Exp Ther Med. 4:633–639. 2012.
|
|
17
|
Ghiţă C, Vîlcea ID, Dumitrescu M, et al:
The prognostic value of the immunohistochemical aspects of tumor
suppressor genes p53, bcl-2, PTEN and nuclear proliferative antigen
Ki-67 in resected colorectal carcinoma. Rom J Morphol Embryol.
53:549–556. 2012.
|
|
18
|
Al-Maghrabi J, Al-Ahwal M, Buhmeida A, et
al: Expression of cell cycle regulators p21 and p27 as predictors
of disease outcome in colorectal carcinoma. J Gastrointest Cancer.
43:279–287. 2012.
|
|
19
|
Zlobec I, Minoo P, Baumhoer D, et al:
Multimarker phenotype predicts adverse survival in patients with
lymph node-negative colorectal cancer. Cancer. 112:495–502.
2008.
|
|
20
|
Wang MT, Chen G, An SJ, et al: Prognostic
significance of cyclinD1 amplification and the co-alteration of
cyclinD1/pRb/ppRb in patients with esophageal squamous cell
carcinoma. Dis Esophagus. 25:664–670. 2012.
|
|
21
|
Sugimoto M, Martin N, Wilks DP, et al:
Activation of cyclin D1-kinase in murine fibroblasts lacking both
p21(Cip1) and p27(Kip1). Oncogene. 21:8067–8074. 2002.
|
|
22
|
Mao Y, Li Z, Lou C and Zhang Y: Expression
of phosphorylated Stat5 predicts expression of cyclin D1 and
correlates with poor prognosis of colonic adenocarcinoma. Int J
Colorectal Dis. 26:29–35. 2011.
|
|
23
|
Belt EJ, Brosens RP, Delis-van Diemen PM,
et al: Cell cycle proteins predict recurrence in stage II and III
colon cancer. Ann Surg Oncol. 19(Suppl 3): S682–S692. 2012.
|
|
24
|
Weng LP, Brown JL and Eng C: PTEN
coordinates G(1) arrest by down-regulating cyclin D1 via its
protein phosphatase activity and up-regulating p27 via its lipid
phosphatase activity in a breast cancer model. Hum Mol Genet.
10:599–604. 2001.
|
|
25
|
Lan YT, Yang SH, Chang SC, et al: Analysis
of the seventh edition of American Joint Committee on colon cancer
staging. Int J Colorectal Dis. 27:657–653. 2011.
|
|
26
|
Bertagnolli MM, Warren RS, Niedzwiecki D,
et al: p27Kip1 in stage III colon cancer: implications for outcome
following adjuvant chemotherapy in cancer and leukemia group B
protocol 89803. Clin Cancer Res. 15:2116–2122. 2009.
|
|
27
|
Li D, Zhang Y, Xie Y, et al: Enhanced
tumor suppression by adenoviral PTEN gene therapy combined with
cisplatin chemotherapy in small-cell lung cancer. Cancer Gene Ther.
20:251–259. 2013.
|
|
28
|
Zhu L, Loo WT and Louis WC: PTEN and VEGF:
possible predictors for sentinel lymph node micro-metastasis in
breast cancer. Biomed Pharmacother. 61:558–561. 2007.
|
|
29
|
Hsu CP, Kao TY, Chang WL, et al: Clinical
significance of tumor suppressor PTEN in colorectal carcinoma. Eur
J Surg Oncol. 37:140–147. 2011.
|
|
30
|
Jung SM, Park SS, Kim WJ and Moon SK:
Ras/ERK1 pathway regulation of p27KIP1-mediated G1-phase cell-cycle
arrest in cordycepin-induced inhibition of the proliferation of
vascular smooth muscle cells. Eur J Pharmacol. 681:15–22. 2012.
|
|
31
|
Tsutsui S, Inoue H, Yasuda K, et al:
Inactivation of PTEN is associated with a low p27Kip1 protein
expression in breast carcinoma. Cancer. 104:2048–2053. 2005.
|
|
32
|
Zolota VG, Tzelepi VN, Leotsinidis M, et
al: Histologic-type specific role of cell cycle regulators in
non-small cell lung carcinoma. J Surg Res. 164:256–265. 2010.
|
|
33
|
Shapira M, Ben-Izhak O, Linn S, et al: The
prognostic impact of the ubiquitin ligase subunits Skp2 and Cks1 in
colorectal carcinoma. Cancer. 103:1336–1346. 2005.
|
|
34
|
Engin H, Baltali E, Güler N, et al:
Expression of PTEN, cyclin D1, P27/KIP1 in invasive ductal
carcinomas of the breast and correlation with clinicopathological
parameters. Bull Cancer. 93:E21–E26. 2006.
|
|
35
|
Ioachim E: Expression patterns of cyclins
D1, E and cyclin-dependent kinase inhibitors p21waf1/cip1, p27kip1
in colorectal carcinoma: correlation with other cell cycle
regulators (pRb, p53 and Ki-67 and PCNA) and clinicopathological
features. Int J Clin Pract. 62:1736–1743. 2008.
|
|
36
|
Hwang TS, Han HS, Hong YC, et al:
Prognostic value of combined analysis of cyclin D1 and estrogen
receptor status in breast cancer patients. Pathol Int. 53:74–80.
2003.
|
|
37
|
Sherr CJ and Roberts JM: CDK inhibitors:
positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999.
|
|
38
|
Halvorsen OJ, Haukaas SA and Akslen LA:
Combined loss of PTEN and p27 expression is associated with tumor
cell proliferation by Ki-67 and increased risk of recurrent disease
in localized prostate cancer. Clin Cancer Res. 9:1474–1479.
2003.
|
|
39
|
Fiano V, Ghimenti C, Imarisio S, et al:
pAkt, cyclin D1 and p27/Kip. 1 in glioblastomas with and without
EGFR amplification and PTEN mutation. Anticancer Res. 24:2643–2647.
2004.
|
|
40
|
Ye YW, Wu JH, Wang CM, et al: Sox17
regulates proliferation and cell cycle during gastric cancer
progression. Cancer Lett. 307:124–131. 2011.
|
